PHAT Share Price Performance
US$17.66
9.56 (118.02%)
22.9% undervalued intrinsic discount
US$22.90
Fair Value
Price US$17.66
AnalystConsensusTarget US$22.90
AnalystLowTarget US$12.00
AnalystHighTarget US$29.00
Fair ValueUS$22.90
Share Pricen/a
Phathom Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
PHAT Community Narratives
AN
Fair Value US$22.9 22.9% undervalued intrinsic discount
PHAT: Rising Profit Margins Will Drive Stronger Shareholder Value Ahead
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
Fair Value US$12 47.2% overvalued intrinsic discount
Rising Pricing Pressure And Regulatory Hurdles Will Impair GI Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$29 39.1% undervalued intrinsic discount
Aging Demographics And Emerging Markets Will Boost GI Adoption
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
PHAT: Rising Profit Margins Will Drive Stronger Shareholder Value Ahead
Key Takeaways Strategic focus on high-need gastroenterology segments and new indications aims to drive rapid adoption and expand long-term market potential. Extended product exclusivity and cost-optimization efforts are expected to sustain high-margin growth and accelerate the path to profitability.Read more
79
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
US$22.9
22.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
66.14% p.a.
Profit Margin
33.04%
Future PE
9.42x
Price in 2028
US$27.71
Aging Demographics And Emerging Markets Will Boost GI Adoption
Key Takeaways Expanding adoption among gastroenterologists, longer exclusivity for key drugs, and global demographic trends could drive sustained, above-expected revenue and profit growth. Strategic international partnerships and strong cost discipline position the company for early profitability and significant operating leverage.Read more
7
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$29
39.1% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
85.68% p.a.
Profit Margin
28.97%
Future PE
12.86x
Price in 2028
US$34.31
Rising Pricing Pressure And Regulatory Hurdles Will Impair GI Prospects
Key Takeaways Margin pressure is mounting amid global price sensitivity, stricter reimbursement, and high R&D costs, limiting Phathom's growth and profitability prospects. Heavy dependence on a narrow GI drug pipeline exposes Phathom to significant concentration risk and future revenue uncertainties.Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$12
47.2% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
60.35% p.a.
Profit Margin
23.22%
Future PE
10.3x
Price in 2028
US$14.2
Trending Discussion
Recently Updated Narratives
AN
PHAT: Late-Stage Gastrointestinal Pipeline Progress Will Drive Upside Momentum
Fair Value: US$22.9 22.9% undervalued intrinsic discount
8 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Pricing Pressure And Regulatory Hurdles Will Impair GI Prospects
Fair Value: US$12 47.2% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Demographics And Emerging Markets Will Boost GI Adoption
Fair Value: US$29 39.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Phathom Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -3.94
- 87.25%
- -186.53%
- -137.4%
About PHAT
- Founded
- 2018
- Employees
- 427
- CEO
- WebsiteView website
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
